Overt

OverT Bio is a clinical-stage biotechnology company developing next-generation, programmed off-the-shelf (allogeneic) cell therapies and biologics for solid tumors. The company pairs AI-powered genome-scale genetic discovery with tumor-targeting receptor engineering and naturally tumor-homing gamma delta T cells, plus scalable manufacturing intended to reduce treatment time and cost. Its pipeline includes OVT-101, a CLDN6-targeted CAR-T for ovarian cancer (first-in-human anticipated H1 2027), and OVT-201, a non-MHC T cell engager for solid tumors. Based in New York City and backed by Wing Venture Capital. As a therapeutics company, OverT Bio publishes no public API, developer portal, SDKs, or machine-readable specifications.

Overt is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Cell Therapy, Immunotherapy, and Oncology.

🌐 Visit website 📡 Source on GitHub

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

CompanyBiotechnologyCell TherapyImmunotherapyOncologyLife SciencesDrug DiscoveryArtificial Intelligence

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 2.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/overt: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: overt
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/overt.png
name: Overt
description: OverT Bio is a clinical-stage biotechnology company developing next-generation, programmed off-the-shelf (allogeneic)
  cell therapies and biologics for solid tumors. The company pairs AI-powered genome-scale genetic discovery with tumor-targeting
  receptor engineering and naturally tumor-homing gamma delta T cells, plus scalable manufacturing intended to reduce treatment
  time and cost. Its pipeline includes OVT-101, a CLDN6-targeted CAR-T for ovarian cancer (first-in-human anticipated H1 2027),
  and OVT-201, a non-MHC T cell engager for solid tumors. Based in New York City and backed by Wing Venture Capital. As a
  therapeutics company, OverT Bio publishes no public API, developer portal, SDKs, or machine-readable specifications.
url: https://raw.githubusercontent.com/api-evangelist/overt/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- wing-venture-capital
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Cell Therapy
- Immunotherapy
- Oncology
- Life Sciences
- Drug Discovery
- Artificial Intelligence
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.overt.bio/
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1